In an otherwise treatment-refractory population, the combination shows favorable overall response rates in patients with mantle cell lymphoma.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/refractory-mantle-cell-lymphoma-mosunetuzumab-polatuzumab-2025a1000nsk?src=rss
Author :
Publish date : 2025-09-09 13:33:00
Copyright for syndicated content belongs to the linked Source.